Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Lancet Haematol. 2021 Aug;8(8):e562–e571. doi: 10.1016/S2352-3026(21)00170-8

Table 2 –

Response at end of study therapy

Clinical response, n (%) [95% CI]
Characteristic CR PR SD PD ORR
Overall (n=43) 32 (74%)
[58.8–86.5%]		 7 (16%)
[6.8–30.7%]		 4 (9%)
[2.6–22.1%]		 0 (0%)
[0–8.2%]		 39 (91%)
[77.9%–97.4%]
Response to primary therapy
Primary refractory (n=28) 19 (68%)
[47.6–84.1%]		 5 (18%)
[6.1–36.9%]		 4 (14%)
[4–32.7%]		 0 (0%)
[0–12.3%]		 24 (86%)
[67.3–96%]
Relapse 3–12 months (n=8) 8 (100%)
[63.1–100%]		 0 (0%)
[0–36.9%]		 0 (0%)
[0–36.9%]		 0 (0%)
[0–36.9%]		 8 (100%)
[63.1–100%]
Relapse > 12 months (n=7) 5 (71%)
[29–96.3%]		 2 (29%)
[3.7–71%]		 0 (0%)
[0–41%]		 0 (0%)
[0–41%]		 7 (100%)
[59–100%]
ASCT
Yes(n=37) 3 (50%)
[11.8–88.2%]		 1 (17%)
[0.4–64.1%]		 2 (33%)
[4.3–77.7%]		 0 (0%)
[0–45.9%]		 4 (67%)
[22.3–95.7%]
No (n=6) 29 (78%)
[61.8–90.2%]		 6 (16%)
[6.2–32%]		 2 (5.4%)
[0.7–18.2%]		 0 (0%)
[0–9.5%]		 35 (95%)
[81.8–99.3%]